

Supplementary Table 2. Clinical characteristics of RNA-seq participants.

| | HIV-negative | | HIV-positive | | P |
|--|--------------|------------|--------------|-------------|--------------------|
| | Young | Older | Young | Older | |
| Female | 4 (57.14) | 2 (50.00) | 3 (75.00) | 0 (0.00) | 0.256 ¹ |
| Race | | | | | |
| Black | 3 (42.86) | 2 (50.00) | 2 (50.00) | 2 (50.00) | 0.593 ¹ |
| White | 3 (42.86) | 2 (50.00) | 0 (0.00) | 2 (50.00) | |
| Other | 1 (14.29) | 0 (0.00) | 2 (50.00) | 0 (0.00) | |
| Latinx | 2 (28.57) | 1 (25.00) | 2 (50.00) | 1 (25.00) | 0.917 ¹ |
| BMI Mean (SD) | 27.1 (2.9) | 35.0 (5.6) | 29.2 (14.5) | 26.7 (4.9) | 0.624 ² |
| BMI >= 30kg/m2 | 1 (14.29) | 3 (75.00) | 1 (25.00) | 1 (25.00) | 0.252 ¹ |
| DM2 | 1 (14.29) | 3 (75.00) | 1 (25.00) | 1 (25.00) | 0.252 ¹ |
| Metabolic Syndrome | 0 (0.00) | 4 (100.00) | 1 (25.00) | 0 (0.00) | 0.002 ¹ |
| CAD and/or PVD | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2 (50.00) | 0.105 ¹ |
| Asthma and/or COPD | 2 (28.57) | 2 (50.00) | 1 (25.00) | 3 (75.00) | 0.518 ¹ |
| Autoimmune and/or autoinflammatory disease | 1 (14.29) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1.000 ¹ |
| Prior Smoker | 1 (14.29) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1.000 ¹ |
| Current Smoker | 3 (42.86) | 1 (25.00) | 0 (0.00) | 2 (50.00) | 0.583 ¹ |
| Recreational drug use in past year | 3 (42.86) | 0 (0.00) | 1 (25.00) | 1 (25.00) | 0.711 ¹ |
| History of positive PPD or Quantiferon | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2 (50.00) | 0.105 ¹ |
| History of fungal disease | 1 (14.29) | 0 (0.00) | 3 (75.00) | 0 (0.00) | 0.047 ¹ |
| CD4 >200 | | | 4 (100.00) | 4 (100.00) | NA ¹ |
| VL > 100 | | | 1 (25.00) | 0 (0.00) | 1.000 ¹ |
| on HAART | | | 4 (100.00) | 4 (100.00) | NA ¹ |
| % life span with HIV [Mean (SD)] | | | 63.3 (43.6) | 44.0 (13.6) | 0.008 ³ |
| Congenital HIV | | | 2 (50.00) | 0 (0.00) | 0.429 ¹ |

¹Fisher's Exact Test.

²ANOVA.

³T-test.

Fungal disease was defined as fungal infections other than superficial cutaneous infections (e.g. tinea pedis). Abbreviations: BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; HLD, hyperlipidemia; HTN, hypertension; PPD, purified protein derivative; PVD, peripheral vascular disease; VL, viral load.

Supplementary Table 3. Demographics of all cohorts stratified by both age and HIV-status.

| | | Monocytes | | | | p-value | Dendritic cells | | | | p-value |
|-------------------------------------|----------|------------|-------------------|------------|---------------------|--------------------|-----------------|--------------------|------------|---------------------|--------------------|
| | | Younger | | Older | | | Younger | | Older | | |
| | | Negative | Positive | Negative | Positive | | Negative | Positive | Negative | Positive | |
| Gender | Male | 8 (38.10) | 8 (57.14) | 12 (50.00) | 13 (59.09) | 0.534 ¹ | 8 (38.10) | 6 (60.00) | 11 (61.11) | 10 (58.82) | 0.449 ² |
| | Female | 13 (61.90) | 6 (42.86) | 12 (50.00) | 9 (40.91) | | 13 (61.90) | 4 (40.00) | 7 (38.89) | 7 (41.18) | |
| Race/Ethnicity | Hispanic | 1 (4.76) | 5 (35.71) | 2 (8.33) | 5 (22.73) | 0.057 ² | 1 (4.76) | 4 (40.00) | 0 (0.00) | 1 (5.88) | 0.004 ² |
| | White | 16 (76.19) | 4 (28.57) | 17 (70.83) | 10 (45.45) | 0.000 ² | 16 (76.19) | 2 (20.00) | 16 (88.89) | 11 (64.71) | 0.000 ² |
| | Black | 1 (4.76) | 6 (42.86) | 5 (20.83) | 9 (40.91) | 0.000 ² | 1 (4.76) | 4 (40.00) | 2 (11.11) | 5 (29.41) | |
| | Asian | 4 (19.05) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0.000 ² | 4 (19.05) | 0 (0.00) | 0 (0.00) | 0 (0.00) | |
| | Other | 0 (0.00) | 4 (28.57) | 2 (8.33) | 3 (13.64) | 0.000 ² | 0 (0.00) | 4 (40.00) | 0 (0.00) | 1 (5.88) | |
| Smoking | | 1 (4.76) | 5 (35.71) | 4 (16.67) | 4 (18.18) | 0.126 ² | 1 (4.76) | 3 (30.00) | 2 (11.11) | 4 (23.53) | 0.183 ² |
| Recreational Drugs | | 1 (4.76) | 5 (35.71) | 1 (4.17) | 6 (27.27) | 0.011 ² | 1 (4.76) | 3 (30.00) | 0 (0.00) | 6 (35.29) | 0.004 ² |
| Fungal Disease | | 0 (0.00) | 1 (7.14) | 0 (0.00) | 3 (13.64) | 0.081 ² | 0 (0.00) | 1 (10.00) | 0 (0.00) | 6 (35.29) | 0.001 ² |
| | 0 | 5 (23.81) | 0 (0.00) | 1 (4.17) | 0 (0.00) | 0.000 ² | 5 (23.81) | 0 (0.00) | 1 (5.56) | 0 (0.00) | 0.000 ² |
| Number of Comorbidities | 1-3 | 15 (71.43) | 7 (50.00) | 2 (8.33) | 3 (13.64) | | 15 (71.43) | 4 (40.00) | 2 (11.11) | 3 (17.65) | |
| | 4-7 | 1 (4.76) | 6 (42.86) | 11 (45.83) | 13 (59.09) | | 1 (4.76) | 3 (30.00) | 10 (55.56) | 8 (47.06) | |
| | >7 | 0 (0.00) | 1 (7.14) | 10 (41.67) | 6 (27.27) | | 0 (0.00) | 3 (30.00) | 5 (27.78) | 6 (35.29) | |
| History of positive PPD/Quantiferon | | 2 (9.52) | 2 (14.29) | 0 (0.00) | 4 (18.18) | 0.150 ² | 2 (9.52) | 2 (20.00) | 0 (0.00) | 2 (11.76) | 0.318 ² |
| Diabetes | | 0 (0.00) | 1 (7.14) | 11 (45.83) | 7 (31.82) | 0.000 ² | 0 (0.00) | 1 (10.00) | 7 (38.89) | 5 (29.41) | 0.005 ² |
| Metabolic syndrome | | 0 (0.00) | 1 (7.14) | 11 (45.83) | 4 (18.18) | 0.000 ² | 0 (0.00) | 1 (10.00) | 7 (38.89) | 3 (17.65) | 0.006 ² |
| Cardiovascular Disease | | 1 (4.76) | 1 (7.14) | 11 (45.83) | 9 (40.91) | 0.001 ² | 1 (4.76) | 0 (0.00) | 8 (44.44) | 10 (58.82) | 0.000 ² |
| Pulmonary Disease | | 5 (23.81) | 4 (28.57) | 7 (29.17) | 7 (31.82) | 0.972 ² | 5 (23.81) | 2 (20.00) | 4 (22.22) | 5 (29.41) | 0.937 ² |
| CD4 count > 200 | | | 10 (100.00) | | 16 (94.12) | 0.434 ¹ | | 10 (100.00) | | 16 (94.12) | 0.434 ¹ |
| On ART | | | 8 (80.00) | | 17 (100.00) | 0.055 ¹ | | 8 (80.00) | | 17 (100.00) | 0.055 ¹ |
| HIV VL > 100 | | | 8 (80.00) | | 17 (100.00) | 0.055 ¹ | | 8 (80.00) | | 17 (100.00) | 0.055 ¹ |
| % life span with HIV | | | 33.5 (9.7-100) | | 26.1 (23.4-38.1) | 0.850 ³ | | 17.8 (8.3-38.5) | | 38.1 (22.2-50.0) | 0.850 ³ |

¹Chi Square.

²Fisher's Exact.

³Wilcoxon Rank Sum.

Metabolic syndrome = DM + HTN + HLD, PPD = purified protein derivative. All values are n (%). P values less than or equal to 0.05 were considered significant. The age groups include younger = 21-35, and (≥ 60 years) for most experiments (Monocytes). However, the age groups were extended to 21-40 and (≥ 50 years) for the Dendritic cell experiments.

Significance assessed using Chi Square¹ Fisher's Exact Test² and Wilcoxon Rank Sum³.

The value of % life span with HIV (since diagnosis) shown in the table represents an interquartile range, with the median (25 percentile, 75 percentile).

Supplementary Table 4. Multivariable regression model of IL-12 and TNF- α expression in CD11b+CD14+ activated monocytes.

A

| Multiple linear regression results with least square means for IL-12 cytokine outcome in activated monocytes (N=81) | | | | | | |
|--|---------------------------|-----------------------|----------------|--------------------------------------|-----------------------|----------------|
| | Unadjusted model | | | Adjusted model- all variables | | |
| | Parameter estimate | Standard error | P-value | Parameter estimate | Standard error | P-value |
| Age (Older vs Young) | 19.90 | 3.79 | <0.001 | 14.25 | 4.87 | 0.003 |
| HIV (Positive vs Negative) | 23.03 | 4.37 | <0.001 | 13.99 | 6.19 | 0.024 |
| Age x HIV interaction | -15.50 | 5.75 | 0.007 | -9.68 | 6.05 | 0.110 |
| Recreational Drug Use | | | | 1.06 | 4.40 | 0.810 |
| History of Fungal Disease | | | | 4.10 | 6.78 | 0.545 |
| Comorbid conditions | | | | 3.42 | 2.18 | 0.117 |
| % lifespan with HIV | | | | 0.13 | 0.08 | 0.124 |
| Least square means with 95% confidence intervals for interaction results | | | | | | |
| Age/HIV status | Unadjusted model | | | Adjusted model- all variables | | |
| | Mean | LCL | UCL | Mean | LCL | UCL |
| Younger HIV negative | -8.61 | -15.71 | -1.51 | -14.12 | -19.54 | -8.71 |
| Younger HIV positive | 5.38 | -3.14 | 13.90 | 8.90 | 2.26 | 15.54 |
| Older HIV negative | 5.64 | -0.75 | 12.03 | 5.77 | 0.70 | 10.84 |
| Older HIV positive | 9.95 | 3.72 | 16.18 | 13.30 | 8.00 | 18.59 |

B

| Multiple linear regression results with least square means for TNF-α cytokine outcome in activated monocytes (N=81) | | | | | | |
|--|---------------------------|-----------------------|----------------|--------------------------------------|-----------------------|----------------|
| | Unadjusted model | | | Adjusted model- all variables | | |
| | Parameter estimate | Standard error | P-value | Parameter estimate | Standard error | P-value |
| Age (Older vs Young) | 8.75 | 3.30 | 0.008 | 8.78 | 4.15 | 0.035 |
| HIV (Positive vs Negative) | 14.20 | 3.81 | <0.001 | 8.99 | 5.28 | 0.089 |
| Age x HIV interaction | -4.05 | 5.01 | 0.419 | -1.55 | 5.17 | 0.765 |
| Recreational Drug Use | | | | 1.82 | 3.75 | 0.627 |
| History of Fungal Disease | | | | 1.30 | 5.78 | 0.823 |
| Comorbid conditions | | | | -0.90 | 1.86 | 0.629 |
| % lifespan with HIV | | | | 0.12 | 0.07 | 0.104 |
| Least square means with 95% confidence intervals for interaction results | | | | | | |
| Age/HIV status | Unadjusted model | | | Adjusted model- all variables | | |
| | Mean | LCL | UCL | Mean | LCL | UCL |
| Younger HIV negative | -14.49 | -19.21 | -9.76 | -13.18 | -19.24 | -7.12 |
| Younger HIV positive | -0.28 | -6.07 | 5.50 | -4.19 | -11.45 | 3.08 |
| Older HIV negative | -5.74 | -10.16 | -1.32 | -4.40 | -9.85 | 1.06 |
| Older HIV positive | 4.41 | -0.20 | 9.03 | 3.05 | -2.26 | 8.36 |

(A) Table of multivariable regression model for IL-12 expression in Activated Monocytes. (B) Table of multivariable regression model for TNF- α in Activated Monocytes. Tables outline the multivariable regression model with the following variables (Age, HIV status, Age/HIV interaction term), and the following covariates (history of recreational drug use, history of fungal infection, number of co-morbid conditions, and % HIV life span). LCL and UCL = Lower and Upper Confidence limit respectively.